In collaboration with the linac manufacturer Accuray, ScandiDos has developed a solution that improves the quality assurance (QA) of radiotherapy treatments of moving targets. The solution independently simulates the breathing motion of patients, therefore, adding an extra dimension of QA to the already existing product, the ScandiDos Delta4 HexaMotion motion platform. Organs and tissues move around all the time, and so do certain types of tumors in cancer patients.

A tumor can shift a few centimeters while a patient breathes in and out. For this reason, clinics in possession of advanced tumor tracking machines require an equally sophisticated QA system that can recreate tumor movements to ensure the best possible treatment outcome. With the new Independent Motion Platform (IMP) option, ScandiDos, a world leader in QA and dosimetry, will not only be able to provide clinics with an ideal simulation of tumor movement, but also with a simulation of the patient's breathing motion, independent of each other.

ScandiDos QA solutions ensure that the tumor tracking function of the treatment machine works. Delta4 HexaMotion is a motion platform that recreates the movement of the tumor in six dimensions, whereas the Delta4 Phantom+ measures the 4D dose distribution and shows exactly where the dose ends up. The new IMP option for the Delta4 HexaMotion is developed in close collaboration with Accuray, and its purpose is to mimic the breathing of the patient independent of the motion of the tumor.

Thus, providing medical physicists with a realistic pre-treatment verification of the delivered treatment for machines such as Accuray Radixact® with Synchrony®. The Delta4 solutions give clinics the advantage of a complete validation of the motion management technique for smooth and quick implementation. More importantly, however, they provide verification of the dosimetric effects for moving target treatments.